Keywords: Eli Lilly, Boehringer Ingelheim, Humalog, Linagliptin, India, GlaxoSmithKline, Indian acquisition

In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions

Article | 04 October 2011

Print This

The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company Boehringer Ingelheim are entering ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in